Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T06:35:09.925Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidona en el tratamiento de las psicosis en el anciano: una serie de informes clínicos

Published online by Cambridge University Press:  12 May 2020

R. Bullock  and
S. Libretto
R. Bullock
Affiliation:
Centro de Investigación de Kingshill, Hospital Victoria, Okus Road, Swindon, Wiltshire SN14JU, Reino Unido;
S. Libretto
Affiliation:
P0 Box 79, Janssen-Cilag Ltd., Saunderton, High Wycombe, Buckinghamshire HP14 4HJ, Reino Unido
Get access

Resumen

La risperidona es uno de los agentes antipsicóticos atípicos más recientes, que combina un potente antagonismo hacia los receptores para la serotonina y la dopamina. Se muestra eficaz contra los síntomas positivos y negativos de las psicosis esquizofrénicas y otros trastornos psicóticos, y tiene una baja propensión a causar efectos secundarios extrapiramidales. El propósito de estos informes clínicos en pacientes ancianos es proporcionar el beneficio de la experiencia personal con la risperidona al conjunto de las publicaciones y demostrar los tipos de pacientes que se pueden beneficiar del tratamiento. Estos casos se compilaron retrospectivamente a partir de los datos recogidos en la derivación y durante las citas hospitalarias habituales. Esta serie cubre cuatro áreas principales de preocupación en el tratamiento de los ancianos: las dosis bajas de mantenimiento que minimicen la probabilidad de acontecimientos adversos; el tratamiento con éxito de pacientes no controlados antes y que experimentan efectos secundarios con otros antipsicóticos; la posibilidad de tratamiento intermitente en lugar de continuo, y los beneficios para los pacientes, los cuidadores y los servicios sanitarios. En dosis bajas, la risperidona es un tratamiento efectivo y bien tolerado para las psicosis en los pacientes ancianos que mejora la calidad de vida tanto para los pacientes como para sus cuidadores.

Keywords

antipsicotico atipicoancianosgeriátricopsicosisrisperidona
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 5 , June 2002 , pp. 305 - 313
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Allardyce, JMcKeith, IG.Dementia with Lewy bodies. Rev Clin Gerontology 1997;7:163–70.CrossRefGoogle Scholar
Bowden, CRVoina, SJWoestenborghs, Rde Coster, R.Heykants, J.Stimulation by risperidone of rat prolactin secretion in vivo in cultured pituitary cells in vitro. J Pharmacol Exp Ther 1992;262:699–706.Google ScholarPubMed
Chouinard, GJones, BRemington, GBloom, DAddington, DMacEwan, GW, et al.Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.CrossRefGoogle Scholar
Committee on Safety of Medicines. Neuroleptic sensitivity in patients with dementia. Curr Prob Pharmacovig 1994;20:61.Google Scholar
Davidson, MHarvey, PDVervarcke, JGagiano, CAde Hooge, JDBray, G, et al.A long-term, multicentre, openlabel study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000;15:506–14.3.0.CO;2-V>CrossRefGoogle Scholar
Davies, AAdena, MAKeks, NACatts, SVLambert, T.Schweitzer, I.Risperidone versus haloperidol: I. Metaanalysis of efficacy and safety. Clin Ther 1998;20:58–71.CrossRefGoogle Scholar
Davis, JMJanicak, PG.Risperidone A new, novel (and betters) antipsychotic. Psychiatr Ann 1996;26:78–87.Google Scholar
Ereshefsky, LLacombe, S.Pharmacological profile of risperidone. Can J Psychiatry 1993;38:S80–8.Google ScholarPubMed
Gilbert, PLHarris, MJMcAdams, LAJeste, DV.Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173–88.CrossRefGoogle ScholarPubMed
Grant, S.Fitton, A.Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253–73.CrossRefGoogle ScholarPubMed
Hansen, LAGalasko, D.Lewy body disease. Curr Opin Neurol Neurosurg 1992;5:889–94.Google ScholarPubMed
Hoffman, DWWiner, MSTBartels, S.Oxman, TE.Therapeutic dose: serum level relationships of risperidone and active metabolite in a geriatric population. Psychopharmacol Bull 1995;37:525.Google Scholar
Jeste, DVCaligiuri, MPPaulsen, JSHeaton, RKLacro, JPHarris, MJ, et al.Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756–65.CrossRefGoogle ScholarPubMed
Lacro, JPEastham, JHJeste, DVLohr, JB.Newer antipsychotics and antidepressants for elderly people. Curr Opin Psychiatry 1996;9:290–3.CrossRefGoogle Scholar
Lipski, PSDeath, JW.Risperidone in the treatment of agitated and aggressive patients with dementia. Aust J Ageing 1995;13:151–4.CrossRefGoogle Scholar
Mackay, FJWilton, LVPearce, GLFreemantle, SNMann, RD.The safety of risperidone: a post-marketing study on 7684 patients. Human Psychopharmacol 1998;13:413–8.3.0.CO;2-A>CrossRefGoogle Scholar
Madhusoodanan, S.Brecher, MBrenner, RKasckow, JKunik, MNegrón, AK, et al.Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999;7:132–8.CrossRefGoogle ScholarPubMed
Madhusoodanan, SBrenner, RAraujo, LAbaza, A.Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514–6.Google ScholarPubMed
Marder, SRMeibach, RC.Risperidone in the treatment of schizophrenia. AmJ Geriatr Psychiatry 1994;151:825–35.Google ScholarPubMed
McKeith, IFairbairn, APerry, R, et al.Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673–8.CrossRefGoogle ScholarPubMed
Mimms, July 2000.Google Scholar
Netten, ADennett, JKnight, J. 1998. Unit costs of health and social care. Personal Social Services Research Unit, Canterbury, Kent (costs inflated to 1999 values using the Health Inflation Index).Google Scholar
Peuskens, J, the Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712–26.CrossRefGoogle Scholar
Piggott, MAPerry, EKMcKeith, IGMarshall, EPerq, RH.Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity. Lancet 1994;343:1044–5.Google ScholarPubMed
Reilly, JGAyis, SAFerrier, INJones, SJThomas, SHL.QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048–52.CrossRefGoogle ScholarPubMed
Sajatovic, MRamirez, LVernon, LBrescan, DSimon, MJurjus, G.Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996;26:309–17.CrossRefGoogle ScholarPubMed
Schotte, AJanssen, PFMGommeren, WLuyten, WHMLVan Gompel, PLesage, AS, et al.Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57–73.CrossRefGoogle ScholarPubMed
Snoeck, EVan Peer, ASack, MHorton, M, Mannens, Woestenborghs, R, et al.Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995;122:223–9.CrossRefGoogle ScholarPubMed
The Healthcare Financial Management Association & The Chartered Institute of Public Finance and Accountancy. November 1997. The Health Service Financial Database 1997, Institute of Public Finance Ltd, Croydon, (costs inflated to 1999 values using the Health Inflation Index).Google Scholar
Thomas, SHL.Drugs QT interval abnormalities and ventricular arrhythmias. Adv Drug React Toxicol 1994;13:77–102.Google ScholarPubMed
Zarate, CABaldessarini, RJSiegel, AJNakamura, AMcDonald, JMuir-Hutchinson, LA, et al.Risperidone in the elderly: a pharmacoepidemiological study. J Clin Psychiatry 1997;58:311–7.CrossRefGoogle Scholar